| Study Period | 2021 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 18.65 Billion |
| Market Size (2030) | USD 23.81 Billion |
| CAGR (2025 - 2030) | 5.01% |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
China In-vitro Diagnostics (IVD) Market Analysis
The China In Vitro Diagnostics Market size is estimated at USD 18.65 billion in 2025, and is expected to reach USD 23.81 billion by 2030, at a CAGR of 5.01% during the forecast period (2025-2030).
In vitro diagnostics (IVDs) are essential in detecting infectious diseases. A large number of molecular assays and immunoassays are being used for the detection of infections. Due to an increase in the geriatric population and the high burden of chronic and infectious diseases, like diabetes, cancer, and HIV/AIDS, the market studied is anticipated to show significant growth, as these chronic disorders can be diagnosed and monitored using IVD products.
Factors such as the growing burden of chronic and infectious disorders, the rising use of point-of-care (POC) diagnostics, and growing awareness and acceptance of personalized medicine contribute to the market growth of in-vitro diagnostics (IVD) across China.
The increasing burden of infectious disorders led to a high requirement for tests, which boosted the IVD market in the country. For instance, the data published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) in October 2024 reported that over 5,000 pregnant women received a human immunodeficiency virus (HIV) diagnosis, while more than 400,000 were diagnosed with hepatitis B in China in 2023. Some of these women were diagnosed at such advanced stages that they could not access HIV services to prevent transmission to their children. Thus, the high prevalence of infectious disorders like HIV/AIDS and cancer is expected to bring the growth of China's in vitro diagnostics market back to its pre-pandemic level.
Moroever, due to the significant advantages and technological advancements, clinicians widely adopt point-of-care testing, which is anticipated to drive market growth. For instance, through the National Key Research and Development Program of China, the National Natural Science Foundation of China and the Hong Kong Scholars Program, an article published in the Interdisciplinary Medicine Journal in January 2024, highlighted that advanced techniques, including nucleic acid isothermal amplification (ITA), biochip technology, and microfluidic technology, have made it possible to conduct molecular detection at an extremely small scale, significantly improving analysis efficiency and accuracy. The use of methods like genetic testing, tumor biomarker identification, and pathogen detection has been instrumental in providing vital information for the early diagnosis and treatment of diseases. Therefore, such advancements molecular detection technologies, which can provide accurate results and are expected to boost market growth, are likely to be adopted.
Also, the increasing number of product launches with advanced features and collaborations of market players are expected to drive the market. For instance, in September 2024, Amoy Diagnostics Co., Ltd. received approval from the China National Medical Products Administration (NMPA) for its AmoyDx Pan Lung Cancer PCR Panel for the detection of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), and mesenchymal-epithelial transition exon 14 (METex14) skipping mutations in patients with non-small cell lung cancer (NSCLC). Additionally, in September 2023, Shanghai Kehua Bio-engineering Co., Ltd obtained the IVDR CE certificate for Class D high-risk rapid diagnostic product for HIV(1+2) Antibody (Colloidal Gold) V2. Hence, it is likely to be adopted in molecular diagnostic laboratories and is anticipated to drive market growth.
Due to the above-mentioned factors, such as the growing burden of chronic and infectious disorders and technological advancements in POCT products, which boost the demands and utilization associated with product launches, the in vitro diagnostic market in China is expected to grow over the next few years. However, a lack of proper reimbursement and a stringent regulatory framework may hinder market growth.
China In-vitro Diagnostics (IVD) Market Trends
Molecular Diagnostics Segment is Expected to Witness Major Growth in the China In Vitro Diagnostics Market
In diagnostics research, one of the most valuable advancements has been in the form of molecular diagnostic tools. The polymerase chain reaction is at the forefront of molecular diagnostics. The real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to operate at lower costs and ensure better outcomes.
Molecular diagnostic tests look for specific sequences in DNA or RNA, such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and others, that may or may not be linked to a disease. Molecular diagnostics were mainly used to diagnose infectious diseases, and with the rising burden and increasing spread of the COVID-19 pandemic, the segment was at its peak in the country. Molecular diagnostic tests were used to find viral RNAs that are very specific to the SARS-CoV-2 virus, which caused COVID-19.
In addition, the rising burden of infectious disease and growing concerns can be attributed to the segment's growth. For instance, in November 2023, according to the press release by China’s National Health Commission, there was rise in the incidence of respiratory diseases such as influenza, Mycoplasma pneumoniae, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which particularly affected children in the country. Thus, owing to the rising importance to diagnose pathogens in the early stages of development, molecular tests are likely to be adopted across china.
Additionally, collaboration with domestic manufacturers, and new product launches, the molecular diagnostics segment is expected to witness good growth over the forecast period in China.For instance, in November 2023, Roche Diagnostics participated in China International Import Expo (CIIE) and introduced the latest cobas 5800 system, which has a compact size and is based on molecular concepts and is helpful for laboratories by increasing productivity by automation in the workflow and comprised of a broad menu of over 25 assays. Moreover, in March 2023, Jiangsu Bioperfectus Technologies Co., Ltd. introduced 10 new Real Time PCR Kits such as Enterovirus Real-Time PCR Kit, Shigella Dysenteriae Real-Time PCR Kit and Salmoella Typi Real-Time PCR Kit, among others, that have been independently developed by its team, which offer a comprehensive Total PCR Solution for identifying gastrointestinal (GI) pathogens.Thus, such product launches boosts the adoption rate and is anticipated to drive the segment growth.
Therefore, owing to the above-mentioned factors, such as the high burden of respiratory diseases and market player initiatives such as new product launches are expected to drive the segment growth.
Understand The Key Trends Shaping This Market
Download PDF
Cancer/Oncology Segment is Anticipated to Share Significant Growth in the China In Vitro Diagnostics Market
Cancer is the second-leading cause of mortality in China. Early detection of cancer and access to effective anti-cancer treatment can result in higher survival rates and a better quality of life. In vitro diagnostics (IVDs) are tests or medical devices that examine human body specimens and provide critical data for screening, diagnosis, and treatment.
The major factors that are driving market segment growth in China are the rising number of people with cancer, the rising number of products being approved and put on the market, and the rising investments.
The high prevalence of cancer cases in the country is likely to drive the demand for in-vitro diagnostics, which, in turn, will contribute to the segment growth. For instance, according to the data updated by the Global Cancer Observatory in February 2024, around 5.13 million new cancer cases were expected to be diagnosed in China in 2025 and will reach 5.72 million by 2030. Additionally, according to the Information Centre on HPV and Cancer, in March 2023, approximately 109,741 women were diagnosed with cervical cancer every year in China, and cervical cancer is ranked at 6th position for its prevalence among Chinese women. The high prevalence of cancer will directly increase the demand for early diagnosis, thus helping the market grow during the study period.
Additionally, the growing number of product launches in the region and the high concentration of key players in China act as major factors in driving the market. For instance, in October 2024, the National Medical Products Administration (NMPA) of China approved LungCure CDx, a companion diagnostic based on next-generation sequencing (NGS), to assist in the administration of sunvozertinib (DZD9008) for non–small cell lung cancer (NSCLC) that has positive EGFR exon 20 insertion mutations. Moreover, in September 2023, Grande Bio-tech Co. Ltd., a Hong Kong-based company, invested in Oncgnostics GmbH to develop cancer diagnostics GynTect for accurately screening cervical cancer. Gyntect test received approval in the Chinese market. Thus, such product approvals by the market players are expected to bolster the segment growth in the country.
Therefore, due to the above-mentioend factors such as the increasing burden of cancer and significant investments for product launches, the cancer/oncology segment is expected to grow significantly in China over the next few years.
Get Analysis on Important Geographic Markets
Download PDF
China In-vitro Diagnostics (IVD) Industry Overview
The Chinese in vitro diagnostic market is moderately competitive and consists of some major players. Many players in this market are trying to expand their product portfolios in order to increase their market share. These companies focus on strategies such as mergers and acquisitions, collaborations, and new product developments. Key players in the Chinese in vitro diagnostics market are F Hoffmann-la Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Biomerieux among others.
China In-vitro Diagnostics (IVD) Market Leaders
-
F Hoffmann-la Roche Ltd
-
Danaher Corporation
-
Thermo Fisher Scientific Inc
-
Biomerieux
-
Abbott Laboratories
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
China In-vitro Diagnostics (IVD) Market News
- November 2024: Roche Diagnostics showcased more than 20 in-vitro diagnostic solutions at China International Import Expo (CIIE) 2024, underscoring its long-term commitment in the Chinese market, along with its aim for technological innovation and advancement. The company presented several products, including the Elecsys AD CSF (cerebrospinal fluid immunoassay), VENTANA FOLR1 (IHC companion diagnostic designed to identify PROC (platinum-resistant ovarian cancer)), the LightCycler PRO System, a qPCR platform created to provide precision and adaptability for research and clinical diagnostic laboratories and cobas pulse, a comprehensive blood glucose management solution equipped with mobile digital health features to enhance patient care.
- August 2024: Roche Diagnostics Products (Suzhou) Co Ltd entered into an agreement with the Suzhou Industrial Park (SIP) Administrative Committee to invest CNY 3 billion (approximately USD 420 million) in the expansion of its current facility in Suzhou, Jiangsu province. This investment underscores the company's dedication to the Chinese market and will be allocated for the construction of new plants aimed at producing reagents and instruments, as well as for the localized manufacturing of essential diagnostic products.
China In-vitro Diagnostics (IVD) Industry Segmentation
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used to diagnose various medical conditions, such as chronic diseases. The China in vitro diagnostics market is segmented by test type, product, usability, application and end-user. By test type, the market is segmented into clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, and other types. By product, the market is segmented into instruments, reagents, and other products. By usability, the market is segmented into disposable IVD devices and reusable IVD devices. By application, the market is segmented into infectious disease, diabetes, cancer/oncology, cardiology, autoimmune disease, nephrology, and other applications. By end user, the market is segmented into diagnostic laboratories, hospitals, and clinics, and other end users. For each segment, the market size is provided in terms of USD value.
| By Test Type | Clinical Chemistry |
| Molecular Diagnostics | |
| Immunodiagnostics | |
| Hematology | |
| Other Types | |
| By Product | Instrument |
| Reagent | |
| Other Products | |
| By Usability | Disposable IVD Devices |
| Reusable IVD Devices | |
| By Application | Infectious Disease |
| Diabetes | |
| Cancer/Oncology | |
| Cardiology | |
| Autoimmune Disease | |
| Nephrology | |
| Other Applications | |
| By End-User | Diagnostic Laboratories |
| Hospitals and Clinics | |
| Other End-Users |
By Test Type
| Clinical Chemistry |
| Molecular Diagnostics |
| Immunodiagnostics |
| Hematology |
| Other Types |
By Product
| Instrument |
| Reagent |
| Other Products |
By Usability
| Disposable IVD Devices |
| Reusable IVD Devices |
By Application
| Infectious Disease |
| Diabetes |
| Cancer/Oncology |
| Cardiology |
| Autoimmune Disease |
| Nephrology |
| Other Applications |
By End-User
| Diagnostic Laboratories |
| Hospitals and Clinics |
| Other End-Users |
Need A Different Region or Segment?
Customize Now
China In Vitro Diagnostics Market Research Faqs
How big is the China In Vitro Diagnostics Market?
The China In Vitro Diagnostics Market size is expected to reach USD 18.65 billion in 2025 and grow at a CAGR of 5.01% to reach USD 23.81 billion by 2030.
What is the current China In Vitro Diagnostics Market size?
In 2025, the China In Vitro Diagnostics Market size is expected to reach USD 18.65 billion.
Who are the key players in China In Vitro Diagnostics Market?
F Hoffmann-la Roche Ltd, Danaher Corporation, Thermo Fisher Scientific Inc, Biomerieux and Abbott Laboratories are the major companies operating in the China In Vitro Diagnostics Market.
What years does this China In Vitro Diagnostics Market cover, and what was the market size in 2024?
In 2024, the China In Vitro Diagnostics Market size was estimated at USD 17.72 billion. The report covers the China In Vitro Diagnostics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the China In Vitro Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
China In Vitro Diagnostics Industry Report
The China In-vitro Diagnostics industry is experiencing significant growth, driven by the increasing demand for diagnostic solutions and the rising prevalence of chronic and infectious diseases. This growth is reflected in the market size and market trends, which show a shift towards preventive healthcare across various end-users, including hospitals, homecare, research institutes, and laboratories. The industry analysis highlights the need for enhanced healthcare facilities, while industry trends indicate opportunities in rapidly growing segments.
Market research and market report data from Mordor Intelligence™ provide a comprehensive industry overview and industry report, showcasing market share and market growth. The competitive landscape reveals that players are adopting organic growth strategies to strengthen their presence, supported by government initiatives aimed at improving healthcare outcomes. The market forecast and market outlook are positive, with industry sales and industry size projected to increase.
The industry information and industry statistics underline the expansion driven by advancements in molecular diagnostics for early disease detection. Stakeholders in the healthcare sector can benefit from the market segmentation and market value insights provided in the report pdf. The report example from Mordor Intelligence™ offers detailed market review and market predictions, ensuring that research companies and other stakeholders are well-informed.
In summary, the China In-vitro Diagnostics market is poised for substantial growth, with market data and industry research indicating a favorable industry outlook. Market leaders are leveraging innovation to meet diverse end-user needs, and the market segmentation highlights the various applications driving this growth. The industry reports and market overview provide a clear understanding of the market dynamics, ensuring that stakeholders can capitalize on the opportunities presented by this evolving market.
